These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 35477147)

  • 1. Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L).
    Hayashi H; Yonesaka K; Nakamura A; Fujimoto D; Azuma K; Sakata S; Tachihara M; Ikeda S; Yokoyama T; Hataji O; Yano Y; Hirano K; Daga H; Okada H; Chiba Y; Sakai K; Nishio K; Yamamoto N; Nakagawa K
    Lung Cancer; 2022 Jun; 168():38-45. PubMed ID: 35477147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs.
    Chen HY; Chen CH; Liao WC; Lin YC; Chen HJ; Hsia TC; Cheng WC; Tu CY
    BMC Pulm Med; 2024 Oct; 24(1):517. PubMed ID: 39415161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
    Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T
    Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
    Blakely CM; Urisman A; Gubens MA; Mulvey CK; Allen GM; Shiboski SC; Rotow JK; Chakrabarti T; Kerr DL; Aredo JV; Bacaltos B; Gee M; Tan L; Jones KD; Devine WP; Doebele RC; Aisner DL; Patil T; Schenk EL; Bivona TG; Riess JW; Coleman M; Kratz JR; Jablons DM
    J Clin Oncol; 2024 Sep; 42(26):3105-3114. PubMed ID: 39028931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).
    Cho JH; Lim SH; An HJ; Kim KH; Park KU; Kang EJ; Choi YH; Ahn MS; Lee MH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    J Clin Oncol; 2020 Feb; 38(5):488-495. PubMed ID: 31825714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis.
    Yi L; Fan J; Qian R; Luo P; Zhang J
    Int J Cancer; 2019 Jul; 145(1):284-294. PubMed ID: 30613959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial.
    Yonesaka K; Hayashi H; Nakamura A; Sato Y; Azuma K; Sakata S; Tachihara M; Ikeda S; Yokoyama T; Ito K; Yano Y; Matsumoto H; Daga H; Hata A; Sakai K; Chiba Y; Nishio K; Yamamoto N; Nakagawa K
    Clin Lung Cancer; 2023 Sep; 24(6):519-527.e4. PubMed ID: 37344331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osimertinib after Chemoradiotherapy in Stage III
    Lu S; Kato T; Dong X; Ahn MJ; Quang LV; Soparattanapaisarn N; Inoue T; Wang CL; Huang M; Yang JC; Cobo M; Özgüroğlu M; Casarini I; Khiem DV; Sriuranpong V; Cronemberger E; Takahashi T; Runglodvatana Y; Chen M; Huang X; Grainger E; Ghiorghiu D; van der Gronde T; Ramalingam SS;
    N Engl J Med; 2024 Aug; 391(7):585-597. PubMed ID: 38828946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.
    Okuma Y; Kubota K; Shimokawa M; Hashimoto K; Kawashima Y; Sakamoto T; Wakui H; Murakami S; Okishio K; Hayashihara K; Ohe Y;
    JAMA Oncol; 2024 Jan; 10(1):43-51. PubMed ID: 37991747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
    Liu J; Jin B; Su H; Qu X; Liu Y
    BMC Cancer; 2019 Jul; 19(1):702. PubMed ID: 31315676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of osimertinib in patients with NSCLC harboring EGFR exon 20 insertion: A multicenter trial of the Korean Cancer Study Group (LU17-19).
    Kim YJ; Kim S; Kim TM; Suh KJ; Kim M; Kim SH; Keam B; Kim DW; Lee JS; Heo DS
    Lung Cancer; 2024 Aug; 194():107870. PubMed ID: 38986212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive
    Yu HA; Paz-Ares LG; Yang JC; Lee KH; Garrido P; Park K; Kim JH; Lee DH; Mao H; Wijayawardana SR; Gao L; Hozak RR; Chao BH; Planchard D
    Clin Cancer Res; 2021 Feb; 27(4):992-1002. PubMed ID: 33046516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overall Survival with Osimertinib in Untreated,
    Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B; Shah R; Cobo M; Lee KH; Cheema P; Tiseo M; John T; Lin MC; Imamura F; Kurata T; Todd A; Hodge R; Saggese M; Rukazenkov Y; Soria JC;
    N Engl J Med; 2020 Jan; 382(1):41-50. PubMed ID: 31751012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402).
    Yokoyama T; Yoshioka H; Fujimoto D; Demura Y; Hirano K; Kawai T; Kagami R; Washio Y; Ishida T; Kogo M; Tomii K; Okuno T; Akai M; Hirabayashi M; Nishimura T; Nakahara Y; Kim YH; Miyakoshi C; Yoshimura K; Hirai T;
    Lung Cancer; 2019 Sep; 135():175-180. PubMed ID: 31446992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.
    Wu YL; Guarneri V; Voon PJ; Lim BK; Yang JJ; Wislez M; Huang C; Liam CK; Mazieres J; Tho LM; Hayashi H; Nhung NV; Chia PL; de Marinis F; Raskin J; Zhou Q; Finocchiaro G; Le AT; Wang J; Dooms C; Kato T; Nadal E; Hin HS; Smit EF; Wermke M; Tan D; Morise M; O'Brate A; Adrian S; Pfeiffer BM; Stroh C; Juraeva D; Strotmann R; Goteti K; Berghoff K; Ellers-Lenz B; Karachaliou N; Le X; Kim TM;
    Lancet Oncol; 2024 Aug; 25(8):989-1002. PubMed ID: 39089305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan.
    Huang YH; Hsu KH; Tseng JS; Yang TY; Chen KC; Su KY; Yu SL; Chen JJW; Chang GC
    Target Oncol; 2022 May; 17(3):295-306. PubMed ID: 35460474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation.
    Kawamura T; Kenmotsu H; Kobayashi H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Mori K; Endo M; Takahashi T
    Invest New Drugs; 2020 Feb; 38(1):194-201. PubMed ID: 31183631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis.
    Wang C; Zhao K; Hu S; Dong W; Gong Y; Xie C
    Oncologist; 2023 Jun; 28(6):e397-e405. PubMed ID: 37116899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Afatinib plus PEM and CBDCA overcome osimertinib resistance in EGFR-mutated NSCLC with high thrombospondin-1 expression.
    Onda N; Nakamichi S; Hirao M; Matsuda K; Matsumoto M; Miyanaga A; Noro R; Gemma A; Seike M
    Cancer Sci; 2024 Aug; 115(8):2718-2728. PubMed ID: 38941131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
    Tanaka K; Asahina H; Kishimoto J; Miyata Y; Uchida T; Watanabe K; Hamai K; Harada T; Tsubata Y; Sugawara S; Kobayashi K; Sugio K; Oizumi S; Okamoto I
    Eur J Cancer; 2021 May; 149():14-22. PubMed ID: 33813328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.